Initial Dose of Sublingual Nitroglycerin for Chest Tightness

Dosing Protocol

The American Heart Association recommends administering one sublingual nitroglycerin tablet (0.4 mg) dissolved under the tongue, which may be repeated approximately every 5 minutes for a total of 3 doses if symptoms persist 1

After 3 doses, an assessment should be made about the need for intravenous nitroglycerin if symptoms persist, as recommended by the American College of Cardiology 1
Continuous cardiac monitoring is essential during nitroglycerin administration, according to the American Heart Association 2

The American College of Cardiology recommends not administering nitroglycerin if systolic blood pressure is <90 mmHg or ≥30 mmHg below baseline, with a strength of evidence level of I 1, 3
The American Heart Association advises avoiding nitroglycerin in patients with severe bradycardia (<50 bpm) or tachycardia (>100 bpm), with a strength of evidence level of IIa 1, 3

The European Society of Cardiology recommends using nitroglycerin spray: 400 μg (2 puffs) every 5-10 minutes as an alternative, with a strength of evidence level of IIb 4, 5

The European Society of Cardiology suggests considering intravenous nitroglycerin therapy (starting at 10-20 μg/min and increasing in increments of 5-10 μg/min every 3-5 minutes until response) if symptoms persist after 3 sublingual doses, with a strength of evidence level of I 4, 5, 2
Obtaining a 12-lead ECG within 10 minutes to evaluate for STEMI or other ischemic changes is recommended by the American College of Cardiology, with a strength of evidence level of I 6, 2

The European Heart Journal reports that headache is frequently associated with nitrates, with a strength of evidence level of IIa 4, 5
The European Journal of Heart Failure advises that hypotension may occur, especially in patients with borderline blood pressure, with a strength of evidence level of IIb 4, 5
Tachyphylaxis (tolerance) is common after 24-48 hours of continuous use, necessitating incremental dosing, as reported by the European Heart Journal, with a strength of evidence level of IIa 4, 5